Teva wins FDA approval for generic schizophrenia drug

March 2009
PharmaWatch: CNS;Mar2009, Vol. 8 Issue 3, p11
Market Research Report
The article reports on the approval of the Teva's generic schizophrenia drug from U.S. Food and Drug Administration. It states that the company was granted to market its generic version of Janssen's antipsychotic agent Risperdal oral solution. It adds that Teva was given a 180-day period to market exclusively.


Related Articles

  • J&J Must Supply More Schizophrenia Drug Data to U.S.  // njbiz;9/1/2008, Vol. 21 Issue 36, p11 

    The article reports that the U.S. Food and Drug Administration has asked New Jersey-based Johnson & Johnson (J&J) to give it more data before the latter can secure approval for a schizophrenia treatment. According to a company statement in August 2008, the FDA did not demand additional studies...

  • Schizophrenia & Psychosis Update.  // PharmaWatch: CNS;Aug2008, Vol. 7 Issue 8, p9 

    The article reports updates related to the pharmaceutical industry in the U.S. Acadia Pharmaceuticals Inc. has reported results from its Phase IIb trial with ACp-104 for the treatment of schizophrenia. Meanwhile, the Food and Drug Administration (FDA) has granted final approval for Teva...

  • Plan B One-Step Update.  // MPR - Pharmacist's Edition;Spring2012, Vol. 6 Issue 1, pA:7 

    The article focuses on the announcement from the U.S. Food and Drug Administration (FDA) regarding the continued availability of Plan B One-Step, a levonorgestrel tablet, from Teva Pharmaceutical Industries Ltd. by prescription only for females less than 17 years old with childbearing potentials.

  • Idled Pharma Plant Re-Opens One Year Later. Van Milligen, Dennis // Processing (08968659);May2011, Vol. 24 Issue 5, p4 

    The article reports that the Teva Pharmaceutical Industries' plant in Irvine, California, has reopened after it was temporarily shutdown when the Food and Drug Administration found it had failed to test for endotoxin in raw materials used in making propofol.

  • Generic Cipro on horizon.  // Drug Store News;1/21/2002, Vol. 24 Issue 1, p37 

    Reports on the tentative approval received by Teva Pharmaceuticals from the United States Food and Drug Administration to market the antibiotic ciprofloxacin.

  • Tentative approval for generic Capozide.  // Drug Store News;8/18/97, Vol. 19 Issue 13, pCP32 

    Discloses that Teva Pharmaceutical Industries Ltd. has received tentative approval from the US Food and Drug Administration to manufacture and market captopril and hydrochlorothiazide tablets, a drug indicated for hypertension.

  • Treanda delivery device incompatibility update.  // Reactions Weekly;Sep2015, Vol. 1569 Issue 1, p9 

    The article informs that the U.S. Food & Drug Administration has published a list of specific closed system transfer devices, syringes, vial adapters and disposable gloves which has been tested by the company Teva Pharmaceuticals and compatible with Treanda Injection solution.

  • Quetiapine.  // AHFS Consumer Medication Information;Jul2020, p1 

    Quetiapine tablets and extended-release (long-acting) tablets are used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Quetiapine tablets and extended-release tablets are also...

  • FDA GRANTS TENTATIVE APPROVAL OF SICOR'S FLUMAZENIL I.  // Worldwide Biotech;Jun2004, Vol. 16 Issue 6, p1 

    Reports on the decision of the U.S. Food and Drug Administration to temporarily approve of an abbreviated new drug application for the Flumazenil Injection from Teva Pharmaceutical Industries Ltd. of Jerusalem, Israel. Use of the Flumazenil Injection; Annual sales performance of the product;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics